文献速递乳腺癌

p38MAPKα基质重编程使转移性乳腺癌对免疫治疗敏感

p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.
PubMed 文献 · Cancer Discov · 2023-01-01

该研究显示p38MAPKα抑制(p38i)以CD4+ T细胞、IFNγ和巨噬细胞依赖的方式重编程转移性肿瘤微环境并限制肿瘤生长。联合OX40激动剂协同减少转移生长并提高总生存;p38i基质特征患者总生存更好,且突变负荷增加时进一步改善。p38i、抗OX40与细胞毒性T细胞联用治愈小鼠转移性疾病并产生长期免疫记忆。

要点

  • p38i以CD4+ T细胞、IFNγ和巨噬细胞依赖方式重编程转移微环境并限制肿瘤生长。
  • p38i联合OX40激动剂协同减少转移生长并提高总生存。
  • p38i基质特征患者总生存更好,突变负荷增加时进一步改善。

核心结论

  • p38MAPKα抑制通过重编程转移性肿瘤微环境限制肿瘤生长,联合OX40激动剂可协同减少转移并提高生存。
  • p38i基质特征患者总生存更好,且突变负荷增加时进一步改善。
  • p38i、抗OX40与细胞毒性T细胞联用可治愈小鼠转移性疾病并产生长期免疫记忆。

研究设计与样本

  • 研究采用基质标记方法和单细胞RNA测序来识别可增强p38i疗效的靶点。
  • 研究在转移性乳腺癌模型中进行,评估p38i单用及联合OX40激动剂的疗效。
  • 研究分析了患者p38i转移基质特征与总生存及突变负荷的关系。

主要发现

  • p38i以CD4+ T细胞、IFNγ和巨噬细胞依赖的方式限制肿瘤生长。
  • p38i联合OX40激动剂协同减少转移生长并提高总生存。
  • 具有p38i转移基质特征的患者总生存更好,且突变负荷增加时进一步改善。
  • p38i、抗OX40与细胞毒性T细胞联用治愈小鼠转移性疾病并产生长期免疫记忆。

临床怎么用

  • 作者认为详细理解基质区室可用于设计有效的抗转移治疗。
  • 作者指出靶向基质p38MAPK通路为释放免疫反应创造了机会。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Metastatic breast cancer is an intractable disease that responds poorly to immunotherapy. We show that p38MAPKα inhibition (p38i) limits tumor growth by reprogramming the metastatic tumor microenvironment in a CD4+ T cell-, IFNγ-, and macrophage-dependent manner. To identify targets that further increased p38i efficacy, we utilized a stromal labeling approach and single-cell RNA sequencing. Thus, we combined p38i and an OX40 agonist that synergistically reduced metastatic growth and increased overall survival. Intriguingly, patients with a p38i metastatic stromal signature had better overall survival that was further improved by the presence of an increased mutational load, leading us to ask if our approach would be effective in antigenic breast cancer. The combination of p38i, anti-OX40, and cytotoxic T-cell engagement cured mice of metastatic disease and produced long-term immunologic memory. Our findings demonstrate that a detailed understanding of the stromal compartment can be used to design effective antimetastatic therapies. SIGNIFICANCE: Immunotherapy is rarely effective in breast cancer. We dissected the metastatic tumor stroma, which revealed a novel therapeutic approach that targets the stromal p38MAPK pathway and creates an opportunity to unleash an immunologic response. Our work underscores the importance of understanding the tumor stromal compartment in therapeutic design. This article is highlighted in the In This Issue feature, p. 1275.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Faget DV, Luo X, Inkman MJ, et al. p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy. Cancer Discov. 2023. PMID: 36883955. doi:10.1158/2159-8290.CD-22-0907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。